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BACKGROUND The use of drug-eluting balloons (DEB) for the treat-
ment of in-stent restenosis (ISR) and lesions in small vessels has not
been extensively investigated in the real-life clinical practice. Ac-
cording to the most recent guidelines, the use of DEB is indicated only
for the treatment of ISR. We aim to report a three-centers “all comers”
registry on the safety and efﬁcacy of DEB in the treatment of ISR and
de novo coronary artery disease.
METHODS Consecutive patients treated with the In.Pact Falcon
(Medtronic Inc., Minneapolis, MN, USA) paclitaxel-eluting balloon
between January 2012 and November 2014 in the centers of Verona,
Mirano and Savona were retrospectively analyzed in our registry. The
measured clinical end-points were cardiac death, myocardial infarc-
tion (MI), target lesion revascularization (TLR), target vessel revas-
cularization (TVR), while procedural success was deﬁned as the ability
to reach, cross and dilate a lesion with the study device, with a re-
sidual stenosis <30% and a ﬁnal TIMI 3 ﬂow in the culprit vessel.
Primary end point of the study was the occurrence of major adverse
cardiac events (MACE), deﬁned as combination of cardiac death, MI,
and TLR, at 12 and 24 months of follow up.
RESULTS A total of 167 lesions were successfully treated in 143 pa-
tients. The mean age was 67 10 years, and 82.5% were males. The
main risk factors were represented by hypertension and dyslipidemia
while 39.4% of patients were diabetics. The 73.5% of the population
had a prior PCI and the main indication for PCI was because of ACS
(73.5% while 26.5% of patients suffered from stable angina). The
predominant indication for DEB use was ISR (75%), mainly focal
(34.1%), involving a DES in the 79% of cases. Procedural success was
achieved in 97.6%. A mean of 1.10.18 DEB were used per patient.
Bailout stenting was required in 2 lesions. No events were recorded
during the hospitalization. Long term follow up was available for
100% of the study population. The overall incidence of MACEs at 12
months was 5.6%, while at 24 months was 9.1%, with an overall event
free survival of 85%. Of interest, the primary endpoint occurred in
18% of patients treated for de novo lesions, against a 5.7% of ISR pa-
tients (p¼0.01). Patients presenting with focal restenosis had anincidence of events comparable to those with more aggressive rest-
enotic pattern (diffuse or proliferative, p¼0.71).
CONCLUSIONS Our results conﬁrm the safety and efﬁcacy at short
and long term follow up of DEBs, especially in patients presenting
with ISR. On the contrary, the use of DEB in de novo lesions is asso-
ciated with a poorer clinical outcome. Larger trials are needed to
conﬁrm our data.
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BACKGROUND drug-coated balloons (DCB) have shown to be a valu-
able alternative to stents for the treatment of in-stent restenosis, and
there is some initial evidence of their efﬁcacy for the treatment of
small coronary vessels. Newer generation DCB were developed to
overcome the reduced deliverability of the previous generation of
devices, warranting an effective drug delivery to the vessel wall.
However, the vast majority of such devices still lack of reliability due
to paucity of clinical data.
METHODS between 2012-2014 all patients intended to be treated with
this type of DCB at 9 italian centers were enrolled in this retrospective
registry. We did not have speciﬁc exclusion criteria. Coronary in-
terventions were performed following the Italian Position paper on DCB-
PCI published in 2014. Primary outcome was the occurrence of target
lesion revascularization (TLR) at the longest available follow up.
RESULTS we enrolled 247 consecutive patients/283 lesions, whose
clinical, angiographic and procedural characteristics are depicted in
Table. At the longest available clinical follow up (average 225 days,
I.Q. ranges 67 days), 5 patients suffered a TLR, all but one managed
with re-PCI (2 with another type of DCB, 2 with DES). We registered
2 cases of cardiac death (one for heart failure and one for fatal
myocardial infarction related to another vessel), 4 non-cardiac
deaths (2 malignancies and 2 intracranial hemorrhages) and no cases
of target vessel myocardial infarction/thrombosis.
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%59.0Age, years 68.99.4 Small vessel disease, % 65.0
Males, % 72.4 Bifurcation (side
branch), %25.0Diabetes Mellitus, % 31.8 Lesion length, mm 163.9
Hypertension, % 79.7 Average vessel
diameter, mmSD
2.70.42History of smoke, % 36.9 Percent diameter
stenosis, %SD
85.99.5LVEF, %SD 53.27.2 Predilatation, % 92.2
Chronic Kidney
disease, %12.3 Pressure, atmospheres 9.4Clinical Presentation:
Stable
coronary artery
disease, %43.3 Duration of balloon
inﬂation, seconds42.511.4NSTEMI, % 50.6 Bailout stenting, % 12.3STEMI, % 4.5 Final percent diameter
stenosis, %9.810.8DES in-stent
restenosis, %28.0 Procedural success, % 97.5BMS in-stent
restenosis, %13.0CONCLUSIONS In this consecutive series of patients, treatment with
a new generation of DCB was found safe and effective in maintaining
good vessel patency at mid-term follow up.
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BACKGROUND Transradial (TR) catheterization has become popular
as a ﬁrst-line approach for coronary angiography due to less bleeding
and access site complications. Recently, the transulnar (TU) approach
has been getting attention as a possible substitute to TR access for
repeat angiographic procedures and in cases of radial artery occlusion.
It also preserves the radial artery for subsequent coronary artery
bypass grafting. In this meta-analysis we attempt to compare safety
and efﬁcacy of TU and TR catheterization.
METHODS Electronic databases were searched for all studies
comparing TU and TR catheterization. A total of 6 studies with 13,285
patients were identiﬁed to be included in this analysis. Outcomes of
interest were major adverse cardiovascular events (MACE), vascular
complications, procedure time, procedure success, and crossover rate.
Odds ratio (OR) or standardized mean difference (SMD) along with
95% conﬁdence intervals (CI) were computed for each outcome. Fixed
and random effects models were used as found appropriate. Sensi-
tivity analysis and bias assessment was done for each outcome.
RESULTS There was no signiﬁcant difference between TR and TU for
MACE [OR 0.83 (CI 0.52 to 1.33), p ¼ 0.43], vascular complications [OR
0.9 (CI 0.61 to 1.32), p ¼ 0.58], crossover rate [OR 1.93 (CI 0.69 to 5.37),
p ¼ 0.21], procedure success [OR 1.17 (CI 0.66 to 2.08), p ¼ 0.61] and
procedure time [SMD -0.14 (CI -0.29 to 0.011), p ¼ 0.07]. Sensitivityanalysis revealed that removal of one study (Geng et al) resulted in a
signiﬁcantly increased summary procedure time in TU catheterization
[SMD -0.21 (CI -0.29 to -0.14), p <0.01]. This study (Geng et al) had
shown a non-signiﬁcant trend towards increase in procedure time in
TR catheterization, which was incongruent with all other studies.
CONCLUSIONS Transulnar catheterization is a safe alternative to
transradial approach and has many potential beneﬁts with similar
rates of procedure success. However, this approach may be associated
with an increased procedure time.
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BACKGROUND Transradial percutaneous coronary intervention (TR-
PCI) is rapidly becoming the gold standard especially in primary percu-
taneous coronary intervention (PCI), where most beneﬁt of the radial
approach can be expected such as reducedmajor bleeding andmortality.
However, transradial access and access-site complications could inﬂu-
ence upper extremity function (UEF). The main objective of this study is
to provide insight in the upper extremity morbidity after TR-PCI. Sec-
ondary objectives are to provide insight in the consequences for func-
tional status, factors inﬂuencing UEF, ﬁnancial costs, and to identify
subjects who might beneﬁt from early referral and treatment.
METHODS This study is a single center prospective cohort study with
a minimum of 490 consecutive patients. All patients will, after base-
line examinations, be treated with the intent of using the radial artery
for PCI access. After the intervention patients will undergo follow-up
after 24 hours, two weeks, one and six months. UEF consist of several
parameters including anatomic integrity, strength, range of motion,
coordination, sensory function and pain. In view of this, we created a
primary endpoint which consists of a combination of parameters,
resulting in a very sensitive binary score for upper extremity
dysfunction (UED). This score was assessed after two weeks as
compared to baseline, using validated examinations and question-
naires. Also, secondary endpoints including spasm, access-site
bleeding and access-site hematoma were assessed.
RESULTS Interim results of 111 patients showed 63 patients (56.8%)
had a positive score for (reversible) UED, of which after two weeks
7 patients (11%) had been referred to a hand rehabilitation specialist
with at the time a Disabilities of Arm, Hand and Shoulder (DASH)
score ranging from 0.9-37.9 points. Long term results need to be
further determined. A multivariate binary logistic regression was
performed to assess the impact of numerous factors on the
endpoint. The strongest predictors were female gender (odds ratio
(OR)¼14.38, 95% conﬁdence interval (CI):2.26-91.47,p¼0.005), pre-
vious percutaneous coronary interventions ((OR)¼7.15, 95%(CI):1.14-
44.9, p¼0.005), and number of skin punctures ((OR)¼8.55,
95%(CI):1.85-39.6, p¼0.006).
